Dr David Albert (AliveCor, Mountain View, CA, USA) discusses why the Arrhythmia Alliance is so important in being patient driven, advocacy focussed and professionally engaged. For more information click here. Disclosures: David Albert is an employee and major stock shareholder of AliveCor. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie […]

As the Heart Rhythm Congress 2022 has just finished, Dr David Albert (AliveCor, Mountain View, CA, USA) shares why the conference is so important in bringing together physicians, nurses, patients, patients advocates and all those interested in the care and diagnosis of arrhythmia patients. Disclosures: David Albert is an employee and major stock shareholder of […]

The PROTECTED-TAVR trial studied the efficacy of using an embolic protection device (Sentinel® cerebral protection system) during transcatheter aortic valve replacement in reducing the incidence of stroke/disabling stroke. In this touchCARDIO interview, we speak with Dr Steven Messe (University of Pennsylvania, Philadelphia, PA, USA) to give a Neurologist’s perspective on the findings of the PROTECTED-TAVR […]

The RADIANCE II trial aimed to build on existing data to demonstrate that ultrasound renal denervation can lower blood pressure in patients with uncontrolled hypertension. In this touchCARDIO interview, we speak with Dr Ajay Kirtane (Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY, USA) to discuss the outcomes of the RADIANCE II trial […]

Despite medications and lifestyle modifications for hypertension, there are still many cases of uncontrolled hypertension. Ultrasound renal denervation has shown to be a tool for reducing blood pressure. In this touchCARDIO interview, we speak with Dr Ajay Kirtane (Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY, USA) to discuss the challenges faced in […]

This FAME 3 substudy aimed to define the value of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) and intravascular imaging for cardiovascular failure. In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the substudy of the FAME 3 trial and the implications for clinical practice.  […]

The impact of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) has been assessed in patients with coronary artery disease (CAD). In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the prognostic value for measuring post-PCI FFR and intravascular imaging in CAD. Click here for part […]

The REVIVED study aimed to assess whether the addition of stents when treating patients with severe ischaemic cardiomyopathy would be beneficial to patient outcomes. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the REVIVED trial, its outcomes and how they will affect the current treatment paradigm.  […]

In an ideal scenario, patients with ischaemic cardiomyopathy would receive specific treatment options beyond the general heart failure management currently in place. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the unmet needs in this population and give an evaluation of surgical and percutaneous revascularization in […]